Emcure Pharmaceuticals delivered robust December-quarter results with consolidated net profit jumping 50% year-on-year to ₹230.5 crore, compared with ₹154 crore in the same quarter last year. The company's revenue from operations rose 20.4% from last year to ₹2,363 crore in the December quarter, compared with ₹1,962 crore a year earlier. Earnings Before Interest Tax Depreciation and Amortisation (EBITDA) climbed 39% from the year-ago period to ₹493 crore, while operating margin expanded to 20.8% from 18% in the same period last year. The sharp profit growth reflects improved operating leverage and better cost efficiencies during the quarter.
According to Emcure Pharma, profit growth was driven by strong traction across key therapies in India and sustained momentum in overseas markets. Domestic formulations revenue increased 15.4% from last year to ₹1,025 crore, led by chronic segments such as cardio and diabetes. The international business grew 24.5% to ₹1,338 crore, with broad-based growth across regions including Emcure's Rest of the World business rising 30.7%, while Europe and Canada posted growth of 29.6% and 12.8%, respectively. The topline growth was supported by steady momentum across core therapeutic segments and continued traction in domestic as well as select international markets.
During the quarter, the company launched Poviztra, a biological injectable semaglutide, in partnership with Novo Nordisk, strengthening its presence in the fast-growing weight management segment. This strategic partnership demonstrates Emcure's focus on expanding its product portfolio in high-growth therapeutic areas. The company continues to invest in products, people and processes while maintaining focus on profitability alongside growth initiatives.
Emcure Pharma shares were trading at ₹1,537.00, up ₹30.80 or 2.04%, reflecting a positive investor response following the strong Q3 performance. The stock movement indicates market confidence in the company's robust financial performance and growth trajectory. The positive market reaction reflects investor appreciation for the company's ability to deliver consistent growth across domestic and international markets while maintaining strong profitability metrics.
